Exogenus Therapeutics

Página Inicial
Portugal
Cantanhede
Exogenus Therapeutics

Seizing the potencial of biology to develop innovative solutions for diseases with high unmet needs

Exogenus Therapeutics is an early-stage research and development company developing healthcare solutions based on Extracellular Vesicles (EVs) and Exosomes. Founded in 2015,
Exogenus is a pioneer in the field of EVs/Exosome-based therapeutics, and a recognized innovator in Umbilical Cord Blood clinical use. Leveraging on its experience and recognition in this space, Exogenus mission is to foster a

new era of EVs/Exosomes-based solutions to solve major healthcare challenges, based on the development of its own products, and providing guidance to other partners developing this type technologies for clinical use.

02/06/2026

🎉 𝗖𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗶𝗻𝗴 𝟭𝟭 𝗬𝗲𝗮𝗿𝘀 𝗼𝗳 Exogenus Therapeutics🎉

Today marks a very special milestone as Exogenus Therapeutics celebrates its 𝟭𝟭𝘁𝗵 𝗮𝗻𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗿𝘆.

Over the past eleven years, our journey has been shaped by a shared vision, scientific excellence, resilience, and the collective efforts of an extraordinary community of people who have believed in our mission from the very beginning.

As we celebrate this anniversary, we reflect with pride on the journey so far and look ahead with enthusiasm to the opportunities and challenges that lie ahead. Together, we remain committed to advancing science, delivering innovation, and creating value for patients, partners, and society.

Thank you to everyone who has been part of the Exogenus Therapeutics story over these remarkable eleven years. This achievement belongs to all of you.

Here's to the next chapter of innovation, growth, and impact.

𝗛𝗮𝗽𝗽𝘆 𝟭𝟭𝘁𝗵 𝗔𝗻𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗿𝘆, Exogenus Therapeutics!

05/05/2026

𝗘𝘅𝗼𝗴𝗲𝗻𝘂𝘀 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝘀𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝗳𝗼𝗿 𝗘𝗜𝗖 𝗣𝗿𝗲-𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗼𝗿 𝗳𝘂𝗻𝗱𝗶𝗻𝗴

We’re excited to share that Exogenus Therapeutics has been selected for funding through the 𝐄𝐈𝐂 𝐏𝐫𝐞-𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐨𝐫 programme! 🎉

The funding will allow us to advance the pre-clinical program of 𝐄𝐱𝐨-𝟏𝟎𝟏 development towards its clinical application in 𝐇𝐞𝐚𝐫𝐢𝐧𝐠 𝐋𝐨𝐬𝐬. We are honoured by this selection and enthusiatic about the possibility of bringing our lead asset to clinical phase of development for another condition with high unmet need!

The 𝐄𝐈𝐂 𝐏𝐫𝐞-𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐨𝐫 aims to strengthen the capacity of early-stage deep tech companies across Horizon Europe widening and associated countries, as well as outermost regions.

We are especially proud to highlight that Portugal was among the countries with the highest number of successful applications, further showcasing the strength and potential of the Portuguese deep tech ecosystem.

Congratulations to all the other Portuguese companies selected under this call!

Read the full article ➡️ https://lnkd.in/dAk79uds

h

29/04/2026

𝗢𝘂𝗿 𝗖𝗘𝗢 𝗶𝘀 𝗮𝗻 𝗶𝗻𝘃𝗶𝘁𝗲𝗱 𝘀𝗽𝗲𝗮𝗸𝗲𝗿 𝗮𝘁 𝗜𝗦𝗖𝗧 𝟮𝟬𝟮𝟲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲

We’re pleased to share that our CEO, Joana RS Correia, is an invited speaker at the Exosomes Scientific Signature Series, a satellite event at the ISCT 2026 conference.

Exosomes Scientific Signature Series brings together global experts to explore the evolving science, translation, and clinical application of extracellular vesicles (EVs) and the broader secretome.

We will share important insights about some of the challenges we faced in the development of Exo-101 towards its clinical application, including lessons learned from interactions with regulators.

If you’re attending, don’t miss the opportunity to connect with Joana!

ISCT, International Society for Cell & Gene Therapy

08/04/2026

Two weeks ago, for the first time, Lisbon hosted both and .

For Exogenus Therapeutics, these were more than just home-base events; they were a window into global interests and an opportunity to showcase local talent. We’ve come away with promising new partnerships and productive discussions that have already started moving forward.

Amidst this momentum, we are honoured to be featured by Labiotech.eu, in an article by Willow Shah-Neville, as one of the 6 biotech companies to watch in Portugal in 2026. Indeed, we have ambitious plans and great news to share this year, stay tuned!
👉 Read the feature here: https://lnkd.in/dD3sJe6D

But visibility is only half the battle. While it is a privilege to be highlighted, we must also be realistic: for Portugal to compete with established European and international hubs, we need more than good science and talent.

We need a robust investment landscape, better interconnectivity, streamlined regulatory support, and an environment where small companies have the resources to scale sustainably.

The energy we felt in Lisbon proves that the potential is undeniable. We want to help make the Portuguese ecosystem as competitive as its scientists deserve.

Let’s keep building and innovating for patients!

26/03/2026

𝗗𝗮𝘆 𝟯 𝗮𝘁 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴 & 𝗗𝗮𝘆 𝟭 𝗮𝘁 𝗟𝗦𝗫 𝗪𝗼𝗿𝗹𝗱 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗘𝘂𝗿𝗼𝗽𝗲

We wrapped up 𝗗𝗮𝘆 𝟯 at #𝗕𝗜𝗢𝗘𝘂𝗿𝗼𝗽𝗲𝗦𝗽𝗿𝗶𝗻𝗴 on a high note, with another round of valuable conversations, strategic insights, and meaningful new connections for the Exogenus Therapeutics team.

At the same time, we are excited to kick off 𝗗𝗮𝘆 𝟭 at 𝗟𝗦𝗫 𝗪𝗼𝗿𝗹𝗱 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗘𝘂𝗿𝗼𝗽𝗲 𝟮𝟬𝟮𝟲, right here in Lisbon. This marks an important moment for us as we continue to build momentum around our lead asset 𝗘𝗫𝗢-𝟭𝟬𝟭, advancing towards clinical translation and preparing for the next stage of growth.

As we engage with investors, partners, and industry leaders across both events, our focus remains clear:
✅ Driving forward 𝗘𝗩-𝗯𝗮𝘀𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 into the clinic
✅ Scaling our 𝗚𝗠𝗣-𝗿𝗲𝗮𝗱𝘆 process capabilities
✅ Establishing strong partnerships to support our upcoming clinical milestones

A big thank you to everyone who has been part of these discussions so far — it’s inspiring to see such strong alignment across the biotech and investment communities.

𝗢𝘂𝗿 𝗖𝗘𝗢, Joana RS Correia, 𝗶𝘀 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝘁𝗼 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗻𝗴 𝗼𝘂𝗿 𝗮𝗺𝗯𝗶𝘁𝗶𝗼𝘂𝘀 𝗿𝗼𝗮𝗱𝗺𝗮𝗽 𝗳𝗼𝗿 𝗘𝗫𝗢-𝟭𝟬𝟭 𝗮𝗻𝗱 𝗼𝘂𝗿 𝗽𝗮𝘁𝗵 𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻.

𝗞𝗲𝗲𝗻 𝘁𝗼 𝗱𝗶𝘀𝗰𝘂𝘀𝘀 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁?

25/03/2026

𝗗𝗮𝘆 𝟮 𝗮𝘁 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴: 𝗞𝗲𝗲𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗺𝗼𝗺𝗲𝗻𝘁𝘂𝗺!

𝖠𝗇𝗈𝗍𝗁𝖾𝗋 𝗀𝗋𝖾𝖺𝗍 𝖽𝖺𝗒 𝗈𝖿 𝗂𝗇𝗌𝗂𝗀𝗁𝗍𝖿𝗎𝗅 𝗆𝖾𝖾𝗍𝗂𝗇𝗀𝗌 𝖺𝗇𝖽 𝗌𝗍𝗋𝗈𝗇𝗀 𝖼𝗈𝗇𝗇𝖾𝖼𝗍𝗂𝗈𝗇𝗌 𝖿𝗈𝗋 𝗍𝗁𝖾 Exogenus Therapeutics 𝗍𝖾𝖺𝗆. 𝖶𝖾’𝗋𝖾 𝖾𝗑𝖼𝗂𝗍𝖾𝖽 𝗍𝗈 𝗄𝖾𝖾𝗉 𝖺𝖽𝗏𝖺𝗇𝖼𝗂𝗇𝗀 𝖼𝗈𝗇𝗏𝖾𝗋𝗌𝖺𝗍𝗂𝗈𝗇𝗌 𝖺𝗋𝗈𝗎𝗇𝖽 𝗈𝗎𝗋 𝖤𝖵-𝖻𝖺𝗌𝖾𝖽 𝗍𝗁𝖾𝗋𝖺𝗉𝖾𝗎𝗍𝗂𝖼𝗌 𝖺𝗇𝖽 𝖾𝗑𝗉𝗅𝗈𝗋𝗂𝗇𝗀 𝗇𝖾𝗐 𝗉𝖺𝗋𝗍𝗇𝖾𝗋𝗌𝗁𝗂𝗉 𝗈𝗉𝗉𝗈𝗋𝗍𝗎𝗇𝗂𝗍𝗂𝖾𝗌.

𝖳𝗁𝖺𝗇𝗄 𝗒𝗈𝗎 𝗍𝗈 𝖾𝗏𝖾𝗋𝗒𝗈𝗇𝖾 𝗐𝖾 𝗆𝖾𝗍—𝗅𝗈𝗈𝗄𝗂𝗇𝗀 𝖿𝗈𝗋𝗐𝖺𝗋𝖽 𝗍𝗈 𝖼𝗈𝗇𝗍𝗂𝗇𝗎𝗂𝗇𝗀 𝗍𝗁𝖾 𝖽𝗂𝗌𝖼𝗎𝗌𝗌𝗂𝗈𝗇𝗌!

𝗦𝗲𝗲 𝘆𝗼𝘂 𝗼𝗻 𝗗𝗮𝘆 𝟯!

23/03/2026

𝗗𝗮𝘆 𝟭 𝗮𝘁 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴: 𝗔 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝘃𝗲 𝘀𝘁𝗮𝗿𝘁 𝗶𝗻 𝗟𝗶𝘀𝗯𝗼𝗻!

What an incredible energy to kick off the first day of hashtag #𝗕𝗜𝗢𝗘𝘂𝗿𝗼𝗽𝗲𝗦𝗽𝗿𝗶𝗻𝗴! Being in our home country makes this edition even more special for the Exogenus Therapeutics team, proudly represented on-site by Joana RS Correia (CEO), Patricia C. Freire (Head of Innovation), and Andreia Silva (Head of Research).

Our day was packed with insightful conversations and high-level partnering meetings. We are thrilled to share our vision for 𝗘𝘅𝘁𝗿𝗮𝗰𝗲𝗹𝗹𝘂𝗹𝗮𝗿 𝗩𝗲𝘀𝗶𝗰𝗹𝗲 (𝗘𝗩)-based therapeutics and how we are leading the way with:
✅ The clinical transition of our lead asset 𝗘𝗫𝗢-𝟭𝟬𝟭
✅ Our 𝗚𝗠𝗣-𝗿𝗲𝗮𝗱𝘆 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝘀𝗰𝗮𝗹𝗮𝗯𝗶𝗹𝗶𝘁𝘆

A huge thank you to everyone we met today—the quality of the discussions around regenerative medicine, advanced therapies and biotech investment was truly inspiring.

𝗠𝗶𝘀𝘀𝗲𝗱 𝘂𝘀 𝘁𝗼𝗱𝗮𝘆?
We still have some slots available for Day 2 and 3. If you are looking to explore the future of EV and nanoparticles or discuss strategic partnerships, let's connect!

𝗦𝗲𝗲 𝘆𝗼𝘂 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄 𝗳𝗼𝗿 𝗺𝗼𝗿𝗲!

16/03/2026

𝗢𝗻𝗲 𝘄𝗲𝗲𝗸 𝘁𝗼 𝗴𝗼 𝘂𝗻𝘁𝗶𝗹 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴 𝗶𝗻 𝗟𝗶𝘀𝗯𝗼𝗻

For those who don’t know us yet, Exogenus Therapeutics is a Portuguese biotech company founded in 2015 and pioneering the development of 𝗲𝘅𝘁𝗿𝗮𝗰𝗲𝗹𝗹𝘂𝗹𝗮𝗿 𝘃𝗲𝘀𝗶𝗰𝗹𝗲 (𝗘𝗩)-𝗯𝗮𝘀𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 with a strong translational focus.

Our lead asset, 𝗘𝗫𝗢-𝟭𝟬𝟭, is being developed to address regenerative medicine conditions with significant unmet medical need. We have already reached several key milestones, including:
• A scalable, 𝗚𝗠𝗣-𝗿𝗲𝗮𝗱𝘆 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗽𝗿𝗼𝗰𝗲𝘀𝘀
• 𝗥𝗼𝗯𝘂𝘀𝘁 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝗰𝗼𝗻𝗰𝗲𝗽𝘁 across multiple indications (osteoarthritis hearing loss, lung fibrosis and wound healing)
• 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 of our roadmap toward first-in-human studies in Europe and the USA

𝗘𝗫𝗢-𝟭𝟬𝟭 is now transitioning from preclinical development to clinical validation, with 𝗳𝗶𝗿𝘀𝘁-𝗶𝗻-𝗵𝘂𝗺𝗮𝗻 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 𝗽𝗹𝗮𝗻𝗻𝗲𝗱 𝗳𝗼𝗿 𝗹𝗮𝘁𝗲 𝟮𝟬𝟮𝟳.

Beyond 𝗘𝗫𝗢-𝟭𝟬𝟭, we are expanding our pipeline by developing EV-based solutions for healthcare, specially targeting age-related diseases, and collaborate with strategic partners to support the development of innovative 𝗻𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲-𝗯𝗮𝘀𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀.

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 𝗱𝗶𝗿𝗲𝗰𝘁𝗹𝘆 𝘁𝗼 𝘀𝗰𝗵𝗲𝗱𝘂𝗹𝗲 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝗮𝗻𝗱 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀.

hashtag

12/03/2026

𝗘𝘅𝗼𝗴𝗲𝗻𝘂𝘀 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗮𝘁 𝗟𝗦𝗫 𝗪𝗼𝗿𝗹𝗱 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗘𝘂𝗿𝗼𝗽𝗲 𝟮𝟬𝟮𝟲

Our CEO, Joana RS Correia, will be attending 𝗟𝗦𝗫 𝗪𝗼𝗿𝗹𝗱 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗘𝘂𝗿𝗼𝗽𝗲 𝟮𝟬𝟮𝟲, taking place on 𝟮𝟱–𝟮𝟲 𝗠𝗮𝗿𝗰𝗵 𝗶𝗻 𝗟𝗶𝘀𝗯𝗼𝗻.

Exogenus Therapeutics is 𝗰𝘂𝗿𝗿𝗲𝗻𝘁𝗹𝘆 𝗶𝗻 𝗹𝗮𝘁𝗲 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗽𝗵𝗮𝘀𝗲 𝗼𝗳 𝗘𝘅𝗼-𝟭𝟬𝟭 (𝗼𝘂𝗿 𝗹𝗲𝗮𝗱 𝗮𝘀𝘀𝗲𝘁) having generated robust preclinical data supporting the therapeutic potential for different indications of regenerative medicine, including Osteoarthritis. The company is now 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝘁𝗼𝘄𝗮𝗿𝗱𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻, preparing the regulatory and scientific milestones required to initiate 𝗳𝗶𝗿𝘀𝘁-𝗶𝗻-𝗵𝘂𝗺𝗮𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 𝗶𝗻 𝗹𝗮𝘁𝗲 𝟮𝟬𝟮𝟳.

As we approach this critical inflection point, 𝘄𝗲 𝗮𝗿𝗲 𝗮𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝘀𝗲𝗲𝗸𝗶𝗻𝗴 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 to support the transition from preclinical development into the clinical stage.

𝗜𝗳 𝘆𝗼𝘂 𝗮𝗿𝗲 𝗮𝗻 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿, 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗽𝗮𝗿𝘁𝗻𝗲𝗿, 𝗼𝗿 𝗳𝗲𝗹𝗹𝗼𝘄 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 LSX Europe 𝗮𝗻𝗱 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗲𝗱 𝗶𝗻 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗿𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀, 𝘄𝗲 𝘄𝗼𝘂𝗹𝗱 𝘄𝗲𝗹𝗰𝗼𝗺𝗲 𝘁𝗵𝗲 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗰𝗼𝗻𝗻𝗲𝗰𝘁.

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 𝗱𝗶𝗿𝗲𝗰𝘁𝗹𝘆 𝘁𝗼 𝘀𝗰𝗵𝗲𝗱𝘂𝗹𝗲 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝗮𝗻𝗱 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀.

05/03/2026

𝗘𝘅𝗼𝗴𝗲𝗻𝘂𝘀 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗮𝘁 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴 𝟮𝟬𝟮𝟲 | 𝗟𝗶𝘀𝗯𝗼𝗻 🇵🇹

Exogenus Therapeutics is pleased to announce its participation in 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴 𝟮𝟬𝟮𝟲, taking place this March in Lisbon.

Our team — 𝐉𝐨𝐚𝐧𝐚 𝐂𝐨𝐫𝐫𝐞𝐢𝐚 (𝐂𝐄𝐎), 𝐏𝐚𝐭𝐫𝐢𝐜𝐢𝐚 𝐅𝐫𝐞𝐢𝐫𝐞 (𝐇𝐞𝐚𝐝 𝐨𝐟 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧) and 𝐀𝐧𝐝𝐫𝐞𝐢𝐚 𝐒𝐢𝐥𝐯𝐚 (𝐇𝐞𝐚𝐝 𝐨𝐟 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡) — will be attending, and look forward to engage with strategic partners to discuss our roadmap, upcoming milestones, and investment opportunities to strengthen our product pipeline, and also explore new opportunities for joint innovation.

At Exogenus Therapeutics, we believe that progress in the life sciences is driven by strong, trusted partnerships. BIO-Europe Spring provides a valuable platform to connect, exchange insights, and align on shared ambitions for the future of medicine.

📅 𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴 𝘁𝗼 𝗮𝘁𝘁𝗲𝗻𝗱?
We look forward to connecting face-to-face while in Portugal.

☕ Reach out via platform or contact us directly to schedule a meeting.

h

Endereço

Biocant Park Núcleo 04. Lote 2
Cantanhede
3060-197

Website

http://www.exogenus-t.com/

Notificações

Seja o primeiro a receber as novidades e deixe-nos enviar-lhe um email quando Exogenus Therapeutics publica notícias e promoções. O seu endereço de email não será utilizado para qualquer outro propósito, e pode cancelar a subscrição a qualquer momento.